Gamida Cell

Company Overview

Snapshot

Founded in February 1998, Gamida Cell operates with 51–200 employees and has raised over $416.22 million across 17 funding rounds from 15 investors. The company was acquired by Highbridge Capital Management in March 2024.

Business overview

Gamida Cell is a Health Tech & Life Sciences company pioneering cellular therapy through the use of nicotinamide (NAM) to expand various cell types, including stem cells and natural killer (NK) cells. Its core technology focuses on maintaining the original phenotype and potency of these cells, which has shown improved clinical outcomes such as engraftment time and infection rates in patients receiving umbilical cord blood-derived cells. The company serves the pharmaceutical and healthcare industries, developing treatments for conditions like blood cancers and autoimmune diseases, with products such as Omisirge (omidubicel-onlv) and GDA-201.

Strategic signal

In March 2024, Gamida Cell was acquired by Highbridge Capital Management, signaling a significant strategic shift for the company. This acquisition, which also involved a delisting from NASDAQ, indicates a restructuring process and a new ownership structure for Gamida Cell's cellular and immune therapy development. For investors, this marks a transition from a publicly traded entity to a privately held company under new financial stewardship, potentially impacting its future development and commercialization strategies.

Company Intelligence Q&A

When was Gamida Cell acquired?

Gamida Cell was acquired by Highbridge Capital Management in March 2024.

What was a key product development for Gamida Cell in September 2023?

In September 2023, the first patient received Gamida Cell's Omisirge™ (omidubicel-onlv), an allogeneic cell therapy.

What financial results did Gamida Cell report in November 2023?

In November 2023, Gamida Cell reported its Third Quarter 2023 Financial Results and provided a company update.

What data did Gamida Cell present in November 2023 regarding its therapies?

In November 2023, Gamida Cell presented new data on its allogeneic stem cell therapy omidubicel and natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

What was a significant event for Gamida Cell in October 2018?

In October 2018, Gamida Cell completed an Initial Public Offering on NASDAQ, raising $50 million at a valuation of $210 million.